1. Keller J, Layer P. Human pancreatic exocrine response to nutrients in health and disease. Gut 2005; 54: (Suppl. 6): vi1–vi28.
2. Moreau H, Sauniere JF, Gargouri Y et al. Human gastric lipase: variations induced by gastrointestinal hormones and by pathology. Scand J Gastroenterol 1988; 23: 1044–1048.
3. Carriere F, Barrowman JA, Verger R et al. Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 1993; 105: 876–878.
4. Layer P, von der Ohe MR, Holst JJ et al. Altered postprandial motility in chronic pancreatitis: role of malabsorption. Gastroenterology 1997; 112: 1624–1634.
5. Lankisch PG, Lembcke B, Wemken G et al. Functional reserve capacity of the exocrine pancreas. Digestion 1986; 35: 175–181.
6. Layer P, Peschel S, Schlesinger T et al. Human pancreatic secretion and intestinal motility: effects of ileal nutrient perfusion. Am J Physiol 1990; 258: G196–G201.
7. Layer P, Schlesinger T, Groger G et al. Modulation of human periodic interdigestive gastrointestinal motor and pancreatic function by the ileum. Pancreas 1993; 8: 426–432.
8. Read NW, McFarlane A, Kinsman RI et al. Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 1984; 86: 274–280.
9. Layer P, Jansen JB, Cherian L et al. Feedback regulation of human pancreatic secretion. Effects of protease inhibition on duodenal delivery and small intestinal transit of pancratic enzymes. Gastroenterology 1990; 98: 1311–1319.
10. Layer P, Go VL, DiMagno EP. Fate of pancreatic enzymes during small intestinal aboral transit in humans. Am J Physiol 1986; 251: G475–G480.
11. Holtmann G, Kelly DG, Sternby B et al. Survival of human pancreatic enzymes during small bowel transit: effect of nutrients, bile acids, and enzymes. Am J Physiol 1997; 273: G553–G558.
12. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Dig Dis Sci 2007; 52: 1–17.
13. Zentler-Munro PL, Fitzpatrick WJ, Batten JC et al. Effect of intrajejunal acidity on aqueous phase bile acid and lipid concentrations in pancreatic steatorrhoea due to cystic fibrosis. Gut 1984; 25: 500–507.
14. Bruno MJ. Maldigestion and exocrine pancreatic insufficiency after pancreatic resection for malignant disease: pathophysiology and treatment. Pancreatology 2001; 1: (Suppl. 1): 55–61.
15. Kalivianakis M, Minich DM, Bijleveld CM et al. Fat malabsorption in cystic fibrosis patients receiving enzyme replacement therapy is due to impaired intestinal uptake of long-chain fatty acids. Am J Clin Nutr 1999; 69: 127–134.
16. Dítě P, Dastych M, Novotný I et al: Changes in serum levels of zinc, selenium, copper and magnesium in individuals with chronic alcoholic and chronic idiopathic pancreatitis. Progress in Medicine 2011; 26: 181–185.
17. Montalto G, Soresi M, Carroccio A et al. Lipoproteins and chronic pancreatitis. Pancreas 1994; 9: 137–138.
18. Gullo L, Tassoni U, Mazzoni G et al. Increased prevalence of aortic calcification in chronic pancreatitis. Am J Gastroenterol 1996; 91: 759–761.
19. Haaber AB, Rosenfalck AM, Hansen B et al. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. Int J Pancreatol 2000; 27: 21–27.
20. Dujsíková H, Novotný I, Tomandl J et al. Chronická pankreatitida a skelet. Vnitř Lék 2010; 56: 656–662.
21. Ewald N, Raspe A et al. Determinants of exocrine pancreatic function as measured by fecal elastase-1 concentration in patients with diabetes mellitus. Eur J Med Res 2009;14: 118–122.
22. Gullo L, Simoni P. A study of pancreatic function among subjects over ninety years of age. Pancreatology 2009; 9: 240–244.
23. Dobrilla G. Management of chronic pancreatitis. Focus on enzyme replacement therapy. Int Pancreatol 1989; 5: (Suppl.): 17–29.
24. Mundlos S, Kuhnelt P, Adler G. Monitoring enzyme replacement treatment in exocrine pancreatic insufficiency using the cholestery octanoate breath test. Gut 1990; 31: 1324–1328.
25. Bruno MJ, Haverkort EB, Tijssen GP et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region. Gut 1998; 42: 92–96.
26. Dominguez-Munoz JE, Iglesias-Garcia J, Iglesias-Rey M et al. Effect of the administration schedule on the therapeutic efficacy of oral pancreatic enzyme supplements in patients with exocrine pancreatic insufficiency: a randomized, threeway crossover study. Aliment Pharmacol Ther 2005; 15: 993–1000.
27. Keller J, Layer P. Pancreatic enzyme supplementation therapy. Curr Treat Options Gastroenterol 2003; 6: 369–374.
28. Delchier JC, Vidon N, Saint-Marc Girardin MF et al. Fate of orally ingested enzymes in pancreatic insufficiency:comparison of two pancreatic enzyme preparations. Aliment Pharmacol Ther 1991; 5: 365–378.
29. Lohr MJ, Hummel FM, Pirilis KT et al. Properties of different pancreatin preparations used in pancreatic exocrine insufficiency. Eur J Gastroenterol Hepatol 2009; 4: 1024–1031.
30. Sikkens ECM, Cahen DL, Knipers EJ et al. Pancreatic enzyme replacement therapy in chronic pancreatitis. Best Practice Res Clin Gastroent 2010; 24: 337–347.
31. Waljee AK, DiWagno MJ, Wu BU et al. Systematic review: pancreatic enzyme treatment of malabsorption associated with chronic pancreatitis. Aliment Pharmacol Ther 2009; 29: 235–246.
32. Bruno MJ, Borm JJ, Hoek FJ et al. Gastric transit and pharmacodynamics of a two-millimeter enteric-coated pancreatin microsphere preparation in patients with chronic pancreatitis. Dig Dis Sci 1998; 43: 203–213.
33. Layer P, Keller J. Lipase supplementation therapy: standards, alternatives, and perspectives. Pancreas 2003; 26: 1–7.
34. Dominguez-Munoz JE, Birckelbach U, Glasbrenner B et al. Effect of oral pancreatic enzyme administration on digestive function in healthy subjects: comparison between two enzyme preparations. Aliment Pharmacol Ther 1997; 11: 403–408.
35. Halm U, Loser C, Lohr M et al. A double--blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 1999; 13: 951–957.
36. Meyer JH, Elashoff. J Human postprandial gastric emptying of 1–3 milimeter spheres. Gastroenterology 1988; 94: 114–119.
37. Ramo OJ, Puolakkainen PA, Seppala K et al. Self-administration of enzyme substitution in the treatment of exocrine pancreatic insufficiency. Scand J Gastroenterol 1989; 24: 688–692.
38. Stead RJ, Skypala I, Hodson ME et al. Enteric coated microspheres of pancreatin in the treatment of cystic fibrosis: comparison with standard enteric coated preparation. Thorax 1987; 42: 533–537.
39. Regan PT, Malagelada JR, DiMagno EP et al. Comparative effects of antacids, cimetidine and enteric coating on the therapeutic response to oral enzymes in severe pancreatic insufficiency. N Engl J Med 1977; 297: 854–858.
40. Stevens T, Conwell DL, Whitcomb DC et al. Pancreatic exocrine function tests. In: UpToDate, Basow, DS (Ed), UpToDate, Waltham, MA, March 2012.
41. Kocna P. Dechové testy – moderní, neinvazivní diagnostika. Interní medicína 2006; 8: 336–341.
42. Braden B. 13C breath tests for the assessment of exocrine pancreatic function. Pancreas 2010; 39: 955–959.
43. Nakamura H, Morifuji M, Murakami Y et al. Usefulness of a 13C-labeled mixed triglyceride breath test for assessing pancreatic exocrine function after pancreatic surgery. Surgery 2009; 145: 168–175.
44. Ishii Y, Kohno T, Ito A et al. Measurement of extra-pancreatic secretory function by 13C-dipeptide breath test. Transl Res 2007; 149: 298–303.
45. Krechler T, Kocna P, Vaníčková Z et al. Stanovení elastázy I ve stolici – využití v diagnostice chronické pankreatitidy. Čas Lék Čes 2006; 145: 480–483.
46. Kocna P, Kohout P Clinical, therapeutical and economical benefit of exocrine pancreatic function tests. Pancreatology 2012; 25: (Suppl.): 44.
47. Smyth RL, van Velzen D, Smyth AR et al. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 8: 85–86.
48. Raimondo M, DiMagno EP. Lipolytic activity of bacterial lipase survives better than that of porcine lipase in human gastric and duodenal content. Gastroenterology 1994; 107: 231–235.
49. Suzuki A, Mizumoto A, Rerknimitr R et al. Effect of bacterial or porcine lipase with low- or high-fat diets on nutrient absorption in pancreatic-insufficient dogs. Gastroenterology 1999; 116: 431–437.
50. Suzuki A, Mizumoto A, Sarr MG et al. Bacterial lipase and high-fat diets in canine exocrine pancreatic insufficiency: a new therapy of steatorrhea? Gastroenterology 1997; 112: 2048–2055.
51. Kuhel DG, Zheng S, Tso P et al. Adenovirus--mediated human pancreatic lipase gene transfer to rat bile: gene therapy of fat malabsorption. Am J Physiol Gastrointest Liver Physiol 2000; 279: G1031–G1036.
52. Maeda H, Danel C, Crystal RG. Adenovirus – mediated transfer of human lipase complementary DNA to the gallbladder. Gastroenterology 1994; 106: 1638–1644.